€8.92
5.19%
L&S, Jun 28, 10:55 pm CET
ISIN
DE0005664809
Symbol
EVT
Index
Sector
Industry

Evotec Share price

€8.98
-0.06 0.66% 1M
-12.54 58.28% 6M
-12.31 57.82% YTD
-11.74 56.66% 1Y
-29.57 76.71% 3Y
-15.62 63.50% 5Y
+5.39 150.35% 10Y
Xetra, Closing price Fri, Jun 28 2024
ISIN
DE0005664809
Symbol
EVT
Index
Sector
Industry

Key figures

Market capitalization €1.59b
Enterprise Value €1.71b
PER (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 2.20
P/S ratio (TTM) P/S ratio 2.05
P/B ratio (TTM) P/B ratio 1.44
Turnover (TTM) Turnover €776.60m
EBIT (operating result TTM) EBIT €-82.68m
Cash position €509.94m
EPS (TTM) EPS €-0.51
P/E ratio expected negative
P/S ratio expected 1.82
EV/Sales expected 1.95
Show more

Is Evotec a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Evotec Share analysis

Unlock scores for free

Analyst opinions

11 Analysts have issued a Evotec forecast:

9x Buy
82%
1x Hold
9%
1x Sell
9%

Analyst opinions

11 Analysts have issued a Evotec forecast:

Buy
82%
Hold
9%
Sell
9%

Financial data from Evotec

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
777 777
-
100%
- Direct costs 620 620
-
80%
157 157
-
20%
- Selling and administrative expenses 173 173
-
22%
- Research and development costs 66 66
-
9%
- -
-
-
- Depreciation and amortization - -
-
-
EBIT (operating result) EBIT -83 -83
-
-11%
Net profit -91 -91
-
-12%

Figures in millions EUR.

Don't miss a thing! We will send you all news about the Evotec share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Evotec Share News

EQS
6 days ago
Frühere Aufträge, die vom DOD an Just – Evotec Biologics vergeben wurden umfassen ein COVID-Projekt, das die Herstellung von Dosen unter engen Zeitvorgaben und begrenzten Ressourcen ermöglichte, und einen Auftrag im Rahmen des beschleunigten Antikörperprogramms (engl. Accelerated Antibodies Progr...
EQS
19 days ago
Über Evotec SE Evotec ist ein Wissenschaftskonzern mit einem einzigartigen Geschäftsmodell, um hochwirksame Medikamente zu erforschen, zu entwickeln und für Patienten verfügbar zu machen. Die multimodale Plattform des Unternehmens umfasst eine einzigartige Kombination innovativer Technologien, D...
EQS
20 days ago
Über Evotec SE Evotec ist ein Wissenschaftskonzern mit einem einzigartigen Geschäftsmodell, um hochwirksame Medikamente zu erforschen, zu entwickeln und für Patienten verfügbar zu machen. Die multimodale Plattform des Unternehmens umfasst eine einzigartige Kombination innovativer Technologien, D...
More Evotec News

Company profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Head office Germany
CEO Mario Polywka
Employees 5,000
Founded 1993
Website evotec.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now